Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and ...

Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and ...

FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...

Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment. As health systems continue expanding the use of ...